Eli Lilly Stock: Is It Still a Buy at $1,400?
Eli Lilly (NYSE:LLY) hit a new high of $1,400 after reporting Q3 revenue of $24.4B, up 39% YoY. The company raised full-year sales guidance to $91-92B but slightly lowered EPS guidance. The stock's 45x earnings multiple raises concerns about future growth being priced in, despite its strong performance driven by GLP-1 drugs.
How this was made
The 30-second read
Why it matters
Guidance raise signals strong demand for GLP‑1 drugs, but EPS cut and high multiple may limit near‑term upside.
Market read
Eli Lilly's guidance update is material for biotech investors and may influence sector sentiment.
What to watch
Potential pipeline expansions beyond GLP‑1 and upcoming product launches may offset earnings multiple worries.
Background
The article reviews Eli Lilly's Q3 performance, highlighting a 39% revenue increase and new guidance figures.
Ticker impact
Eli Lilly raised its full-year revenue guidance to $91‑$92B and EPS guidance to $35‑$36 per share after reporting Q3 results.
potential downside as investors price in valuation risk despite revenue upside
Revenue guidance increase is positive, but EPS reduction and a 45x earnings multiple imply limited upside and heightened risk.
Market effects
Higher GLP‑1 drug sales reinforce bullish outlook for biotech sector but may raise valuation concerns.
U.S. large‑cap pharma index could see modest pressure from valuation concerns.
Limited; primarily affects U.S. pharma and biotech investors.
Counterpoint
Despite valuation concerns, continued growth in GLP‑1 market could justify premium pricing.
Key entities
- companyEli Lilly
Pharmaceutical company reporting Q3 results and new guidance.
